INmune Bio, Inc.
INMBHealthcare|Biotechnology|US
$1.13
-0.04 (-3.83%)
DCF Value
$0.76
Tangible Book / Share
$0.65
Cash / Share
$0.59
Financials
Financial Snapshot
Market Cap
$31.4M
Enterprise Value
$16.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$16.7M
Cash & Investments
$16.3M
Net Cash
$15.1M
Free Cash Flow (TTM)
-$13.6M
Operating CF (TTM)
-$12.9M
Debt/Equity
0.07
Cash Runway & Burn Rate
Cash on Hand
$16.3M
Quarterly Burn
$3.2M
Monthly Burn
$1.1M
Est. Runway
~5.1 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $141.7K | $1.4M | $186.2K | $7.0M | $22.0M | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M | $16.3M | |
| Operating Cash Flow | -$317.4K | -$761.8K | -$2.1M | -$5.4M | -$8.9M | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M | -$12.9M | |
| Free Cash Flow | -$317.4K | -$861.8K | -$2.1M | -$5.4M | -$8.9M | -$43.5M | -$22.7M | -$12.0M | -$33.4M | -$23.6M | -$13.6M | |
| Capital Expenditure | $0.00 | -$100.0K | $0.00 | $0.00 | -$4.00 | -$15.0M | $0.00 | $0.00 | $0.00 | -$1.0M | -$706.0K | |
| Financing Cash Flow | $450.0K | $2.1M | $900.0K | $12.2M | $23.9M | $96.4M | $729.0K | -$4.2M | $18.2M | $27.6M | $2.1M |
R&D Spending
R&D (TTM)
$9.9M
R&D Intensity
—
R&D Growth vs Prior
-51.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $11.0K | $181.0K | $374.0K | $155.0K | $14.0K | $50.0K | $0.00 | |
| R&D Expense | $101.5K | $435.4K | $1.1M | $3.3M | $5.9M | $20.5M | $17.1M | $20.3M | $33.2M | $20.7M | $9.9M | |
| R&D % of Revenue | — | — | — | — | 53790.9% | 11349.7% | 4563.4% | 13079.4% | 236900.0% | 41318.0% | — | |
| SG&A | $126.0K | $546.1K | $9.1M | $4.5M | $6.3M | $8.8M | $9.3M | $9.6M | $9.5M | $10.3M | $9.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $11.0K | $181.0K | $374.0K | $155.0K | $14.0K | $50.0K | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $108.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $11.0K | $181.0K | $374.0K | $155.0K | $14.0K | $50.0K | -$108.0K | |
| R&D | $101.5K | $435.4K | $1.1M | $3.3M | $5.9M | $20.5M | $17.1M | $20.3M | $33.2M | $20.7M | $9.9M | |
| SG&A | $126.0K | $546.1K | $9.1M | $4.5M | $6.3M | $8.8M | $9.3M | $9.6M | $9.5M | $10.3M | $9.4M | |
| Operating Income | -$227.0K | -$981.0K | -$12.4M | -$7.8M | -$12.2M | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$30.9M | -$17.8M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$277.0K | -$831.0K | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M | -$16.7M | |
| Net Income | -$277.0K | -$831.0K | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M | -$16.7M | |
| EPS (Diluted) | -0.05 | -0.07 | -1.11 | -0.89 | -1.01 | -1.88 | -1.52 | -1.67 | -2.11 | -1.86 | -0.62 | |
| EBITDA | -$49.5K | $150.5K | $23.00 | -$7.7M | $0.00 | -$1.2M | -$1.3M | -$267.0K | -$41.5M | -$45.8M | -$16.8M | |
| Shares Out. (M) | 5.11 | 11.22 | 11.22 | 10.27 | 11.99 | 16.13 | 17.93 | 17.98 | 19.94 | 26.59 | 27.81 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $141.7K | $1.4M | $186.2K | $7.0M | $22.0M | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M | $16.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $451.6K | $1.9M | $849.3K | $7.8M | $24.0M | $82.6M | $64.7M | $39.9M | $22.7M | $29.9M | $18.7M | |
| Total Assets | $451.6K | $18.4M | $17.4M | $24.5M | $40.7M | $99.9M | $81.8M | $57.0M | $39.6M | $32.4M | $21.5M | |
| Total Current Liabilities | $600.8K | $309.7K | $823.8K | $700.4K | $1.8M | $4.4M | $10.9M | $18.5M | $7.2M | $8.4M | $2.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.5M | $9.7M | $0.00 | $0.00 | $0.00 | $518.0K | |
| Total Liabilities | $600.8K | $309.7K | $823.8K | $860.5K | $1.9M | $19.7M | $21.7M | $18.9M | $7.5M | $8.8M | $3.4M | |
| Stockholders' Equity | -$149.2K | $18.1M | $16.5M | $23.6M | $38.8M | $80.2M | $60.1M | $38.1M | $32.1M | $23.5M | $18.1M | |
| Retained Earnings | -$326.4K | -$1.2M | -$13.6M | -$21.3M | -$33.4M | -$63.7M | -$91.0M | -$121.0M | -$163.1M | -$209.0M | -$220.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$317.4K | -$761.8K | -$2.1M | -$5.4M | -$8.9M | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M | -$12.9M | |
| Capital Expenditure | $0.00 | -$100.0K | $0.00 | $0.00 | -$4.00 | -$15.0M | $0.00 | $0.00 | $0.00 | -$1.0M | -$706.0K | |
| Free Cash Flow | -$317.4K | -$861.8K | -$2.1M | -$5.4M | -$8.9M | -$43.5M | -$22.7M | -$12.0M | -$33.4M | -$23.6M | -$13.6M | |
| Investing Cash Flow | $0.00 | -$100.0K | $0.00 | $0.00 | $0.00 | -$15.0M | $0.00 | $0.00 | $0.00 | -$1.0M | -$143.0K | |
| Financing Cash Flow | $450.0K | $2.1M | $900.0K | $12.2M | $23.9M | $96.4M | $729.0K | -$4.2M | $18.2M | $27.6M | $2.1M | |
| Issuance of Stock | $100.0K | $2.1M | $900.0K | $12.2M | $24.9M | $80.3M | $699.0K | $775.0K | $27.8M | $27.6M | $67.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $15.0M | $0.00 | -$5.0M | -$10.0M | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $199.6K | $10.0M | $4.1M | $0.00 | $4.8M | $7.1M | $7.4M | $7.6M | $9.9M | -$2.6M | |
| Net Change in Cash | $129.8K | $1.2M | -$1.2M | $6.8M | $15.0M | $52.8M | -$22.7M | -$16.3M | -$14.9M | $3.8M | -$11.4M |
Dilution Tracker
Shares outstanding grew 121.8% over 5 years — significant dilution
Shares Outstanding
28M
5-Year Share Growth
+121.8%
Stock Issuance (TTM)
$67.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 5.11 | 11.22 | 11.22 | 10.27 | 11.99 | 16.13 | 17.93 | 17.98 | 19.94 | 26.59 | 27.81 | |
| Change vs Prior % | — | 119.6% | 0.0% | -8.4% | 16.7% | 34.6% | 11.1% | 0.3% | 10.9% | 33.3% | 4.6% | |
| Stock Issuance | $100.0K | $2.1M | $900.0K | $12.2M | $24.9M | $80.3M | $699.0K | $775.0K | $27.8M | $27.6M | $67.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $199.6K | $10.0M | $4.1M | $0.00 | $4.8M | $7.1M | $7.4M | $7.6M | $9.9M | -$2.6M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | |
| Operating Margin % | — | — | — | — | -111163.6% | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -61738.0% | — | |
| Net Margin % | — | — | — | — | -109990.9% | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% | — | |
| EBITDA Margin % | — | — | — | — | 0.0% | -655.8% | -360.4% | -172.3% | -296635.7% | -91698.0% | — | |
| FCF Margin % | — | — | — | — | -81305.9% | -24035.4% | -6065.8% | -7729.0% | -238292.9% | -47248.0% | — | |
| ROE % | 185.7% | -4.6% | -75.2% | -32.5% | -31.2% | -37.8% | -45.4% | -78.7% | -131.1% | -195.3% | -81.7% | |
| ROA % | -61.3% | -4.5% | -71.6% | -31.4% | -29.8% | -30.4% | -33.4% | -52.6% | -106.4% | -142.0% | -77.5% | |
| ROIC % | -113.0% | -5.4% | -75.2% | -32.6% | -31.4% | -30.5% | -34.2% | -61.2% | -131.3% | -125.7% | -92.2% | |
| R&D / Revenue % | — | — | — | — | 53790.9% | 11349.7% | 4563.4% | 13079.4% | 236900.0% | 41318.0% | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1545.5% | 106.6% | -58.6% | -91.0% | 257.1% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1545.5% | 106.6% | -58.6% | -91.0% | 257.1% | |
| Operating Income | -364.5% | -332.2% | -1168.1% | 37.7% | -57.7% | -138.4% | 11.0% | -14.6% | -43.4% | 27.6% | |
| Net Income | -466.8% | -200.0% | -1397.0% | 38.3% | -57.6% | -150.8% | 10.0% | -9.9% | -40.2% | -9.2% | |
| EPS (Diluted) | -453.1% | -36.7% | -1398.0% | 19.8% | -13.5% | -86.1% | 19.1% | -9.9% | -26.3% | 11.8% | |
| Operating Cash Flow | -1651.7% | -140.0% | -170.3% | -161.5% | -66.1% | -218.7% | 20.4% | 47.2% | -178.5% | 32.3% | |
| Free Cash Flow | -1651.7% | -171.5% | -138.9% | -161.5% | -66.1% | -386.4% | 47.9% | 47.2% | -178.5% | 29.2% | |
| R&D Expense | 0.0% | 328.9% | 153.8% | 197.0% | 80.3% | 247.2% | -16.9% | 18.8% | 63.6% | -37.7% | |
| SG&A Expense | 157.8% | 333.4% | 1563.6% | -50.8% | 41.3% | 39.1% | 5.3% | 3.9% | -1.5% | 8.2% | |
| Total Assets | 3700.8% | 3977.3% | -5.7% | 40.9% | 66.1% | 145.8% | -18.2% | -30.3% | -30.6% | -18.2% | |
| Book Value / Share | -674.0% | 5624.7% | -8.6% | 55.9% | 40.7% | 53.8% | -32.6% | -36.7% | -24.1% | -45.0% | |
| Debt | 0.0% | -100.0% | 0.0% | 0.0% | -5.0% | 9421.3% | 0.5% | -31.8% | -96.3% | 169.3% | |
| Diluted Shares | 2.2% | 119.6% | 0.0% | -8.4% | 16.7% | 34.6% | 11.1% | 0.3% | 10.9% | 33.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High303.90 / 1306.23 / 18766.67
P/B1.74
10Y Low / Med / High1.76 / 2.90 / 5.42
EV/EBITDAAt Loss
EV/Revenue0.00
10Y Low / Med / High205.39 / 1142.29 / 16784.21
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.76
Tangible Book / Share
$0.65
Net Current Assets / Share
$0.55
Graham Net-Net
$0.46
Cash / Share
$0.59
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -147.42 | -107.83 | -7.20 | -6.52 | -17.05 | -5.43 | -4.17 | -6.74 | -2.21 | -0.84 | -1.82 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 18766.67 | 909.04 | 303.90 | 1306.23 | 6652.75 | 829.46 | 0.00 | |
| P/B Ratio | -273.55 | 4.95 | 5.42 | 2.52 | 5.33 | 2.05 | 1.89 | 5.31 | 2.90 | 1.76 | 1.74 | |
| EV/EBITDA | -828.60 | 586.58 | 3889287.22 | -6.87 | 0.00 | -88.42 | -56.98 | -663.13 | -1.75 | -0.39 | -0.97 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 16784.21 | 579.89 | 205.39 | 1142.29 | 5185.75 | 355.12 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-10.59
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $133.3K | $9.5M | $23.9M |
| Net Income | -$19.0M | -$17.2M | -$11.2M |
| EPS | $-0.55 | $-0.77 | $-0.78 |
| # Analysts (EPS) | 2 | 1 | 2 |